Ep. 253, Chapter 4: Infectious Disease + Oncology with Mark Eisner, MD

27:23-END

Vir Biotechnology's oncology strategy centers on overcoming the toxicity of unmasked T-cell engagers in solid tumors using the company’s PRO-XTEN™ masking platform. Vir currently has three clinical-stage programs: a HER2-directed T-cell engager for various HER2-positive tumors, a PSMA-targeted program for metastatic castration-resistant prostate cancer, and an EGFR-targeting TCE for multiple tumor types. Dr. Eisner stresses that masking technology allows for effective tumor killing with minimal toxicity. In 2025 and 2026, Vir's top goals include pivotal trials for hepatitis delta, continuing dose escalation for HER2 and PSMA programs, initiating the EGFR program, and identifying a partner for global development of the company’s hepatitis B functional cure program.